LFCR Deadline: LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit

Core Viewpoint - Lifecore Biomedical, Inc. is facing a class action lawsuit due to alleged false and misleading statements regarding its financial reporting and internal controls during the class period from October 7, 2020, to March 19, 2024 [1][4]. Group 1: Class Action Details - The class action lawsuit has been filed, and investors who purchased Lifecore securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. - The deadline to serve as lead plaintiff in the class action is September 27, 2024, and interested parties must move the Court by this date [2]. Group 2: Allegations Against Lifecore - The lawsuit claims that Lifecore maintained deficient internal controls over financial reporting, leading to the issuance of inaccurate financial statements that would require restatement [4]. - It is alleged that Lifecore's remediation efforts regarding these deficiencies were ineffective, impairing its ability to file periodic reports with the SEC in compliance with NASDAQ requirements [4]. - The lawsuit asserts that Lifecore's financial position and prospects were materially overstated, resulting in public statements that were materially false and misleading [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3].